Video 24 April 2014

IFPMA 2014 interview series ‘The Value of investing in immunization’


Immunization has shown excellent results against infectious diseases such as polio and measles, but continued success requires sustained political and financial commitment. Unfortunately, immunization as a whole remains an unfinished business as too many children are still dying of vaccine preventable diseases. As President and General Manager of Pfizer’s Vaccines and an IFPMA Vaccine CEO Steering Committee member, Ms Susan Silbermann talks about why investing in vaccines is so valuable and how the effective introduction and rollout of new vaccines can save millions of more lives.


The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) represents over 90 innovative pharmaceutical companies and associations across the globe. Based in Geneva, IFPMA has official relations with the United Nations and contributes industry expertise to help the global health community improve the lives of people everywhere. The industry’s two million employees discover, develop, and deliver medicines and vaccines that advance global health.

Learn more

Media Contact

Abigail Jones